NEUROTOXIN COMPOSITIONS FOR USE IN TREATING NEUROLOGIC AND PSYCHIATRIC DISORDERS

1 ) A method of treating a neurological or psychological disorder comprising the steps of administering a botulinum toxin into the stellate ganglion nerve of a mammal to treat at least one of PTSD, Depression, Anxiety, Headache and CRPS; thereby reducing the occurrence of at least one symptom of the disorder.

2 ) The method of claim 1 , wherein the botulinum toxin is native immunotype A.

3 ) The method of claim 2 , wherein the botulinum toxin is administered by injection.

4 ) A method of treating a neurological or psychological disorder comprising administering a botulinum toxin into the stellate ganglion in a subject with a neurological or psychological disorder to thereby treat their symptoms.

5 ) A method of treating a neurological or psychological disorder comprising administering a botulinum toxin into the stellate ganglion wherein the administration is performed without any imaging, by palpating the anterior transverse process of C6, or the Chassagne tubercle, and injecting the botulinum toxin medially.

6 ) A method of treating a neurological or psychological disorder comprising administering a botulinum toxin into the stellate ganglion wherein the administration is performed by imaging the treatment area, and injecting the botulinum toxin medially.

7 ) The method of claim 4 , 5 , or 6 wherein the botulinum toxin is a botulinum toxin type A.

8 ) The method of claim 4 , 5 , or 6 wherein the botulinum toxin is a botulinum toxin type B, C, E, or F.

9 ) The method of claim 7 or 8 , wherein the total dose of the botulinum toxin is 50-250 Units.

10 ) The method of claim 7 or 8 , wherein the total dose of the botulinum toxin is 25-150 Units.

11 ) The method of claim 9 , wherein said botulinum toxin is type A.

12 ) The method of claim 9 , wherein said botulinum toxin is type B.

13 ) The method of claim 9 , wherein said botulinum toxin is type C.

14 ) The method of claim 9 , wherein said botulinum toxin is type E.

15 ) The method of claim 9 , wherein said botulinum toxin is type F.

16 ) The method of claim 1 , wherein said neurological or psychological disorder comprises PTSD.

17 ) The method of claim 1 , wherein said neurological or psychological disorder comprises Depression.

18 ) The method of claim 1 , wherein said neurological or psychological disorder comprises Anxiety.

19 ) The method of claim 1 , wherein said neurological or psychological disorder comprises CRPS.

20 ) The method of claim 1 , wherein said neurological or psychological disorder comprises Headache.

21 ) A method of treating a neurological or psychological disorder comprising the steps of administering a botulinum toxin into the stellate ganglion nerve of a mammal to treat at least one of PTSD, Depression, Anxiety, Headache and CRPS; then administering a local anesthetic to the stellate ganglion nerve of said mammal, thereby reducing the occurrence of at least one symptom of the disorder.

22 ) The method of claim 21 , wherein said local anesthetic comprises lidocaine.

23 ) The method of claim 21 , wherein said botulinum toxin is type A.

24 ) The method of claim 21 , wherein said botulinum toxin is type B.

25 ) The method of claim 21 , wherein said botulinum toxin is type C.

26 ) The method of claim 21 , wherein said botulinum toxin is type E.

27 ) The method of claim 21 , wherein said botulinum toxin is type F.

28 ) The method of claim 21 , wherein said neurological or psychological disorder comprises PTSD.

29 ) The method of claim 21 , wherein said neurological or psychological disorder comprises Depression.

30 ) The method of claim 21 , wherein said neurological or psychological disorder comprises Anxiety.

31 ) The method of claim 21 , wherein said neurological or psychological disorder comprises CRPS.

32 ) The method of claim 21 , wherein said neurological or psychological disorder comprises Headache.

33 ) A method for comparing the efficacy and safety of two different Botulinum toxins, comprising:

measuring a reduction of a neurological or psychological disorder symptom of an individual resulting from administration of a first botulinum neurotoxin;

measuring a reduction of a neurological or psychological disorder symptom of an individual resulting from administration of a second botulinum neurotoxin; and

comparing the reduction in symptoms to determine a difference between the first botulinum neurotoxin and the second botulinum neurotoxin.